Precisely targeting circuitry in schizophrenia.

Phrenix Therapeutics is developing next-generation medicines that rebalance dopaminergic signaling across key brain circuits implicated in schizophrenia and other neuropsychiatric disorders. Our lead program targets schizophrenia’s full symptom burden, with an improved safety profile relative to existing treatments.